restenosis after PCI clinical trials results

iridium-92 versus placebo
SCRIPPS, 1997	catheter-based irradiation with iridium-192 versus placebo	patients with restenosis	double blind Follow-up duration: 6 mo US
WRIST, 2001	intracoronary gamma-radiation with (192)Ir 15 Gy versus placebo	presented with symptoms of angina and angiographic evidence of in-stent restenosis	double blind Follow-up duration: 6 mo
GAMMA-ONE, 2001	intracoronary radiotherapy with iridium-192 versus placebo	patients with in-stent restenosis	double blind Follow-up duration: 9 mo US
SVG-WRIST, 2002	intravascular treatment with a ribbon containing iridium-192 versus placebo	patients with in-stent restenosis in saphenous-vein grafts	double blind Follow-up duration: 12 mo US
Long-WRIST, 2003	gamma radiation with 192Ir versus placebo	patients with diffuse long in-stent restenosis in native coronary arteries (lesion length, 36 to 80 mm)	double blind Follow-up duration: 1 y US
P-32 versus placebo
PREVENT, 2000	intracoronary radiotherapy with the beta-emitting (32)P, 16, 20, or 24 Gy to a depth of 1 mm in the artery wall versus sham procedure	patients with de novo (70%) or restenotic (30%) lesions who were treated by stenting (61%) or balloon angioplasty (39%)	double blind Follow-up duration: 6 mo US
INHIBIT, 2002	intracoronary beta radiation with a phosphorus-32 source versus placebo	patients with in-stent restenosis and successful coronary intervention	double blind Follow-up duration: 9 mo US
START, 2000	intracoronary radiation with 90Sr/90Y source versus placebo	patients with in-stent restenosis	double blind Follow-up duration: 8 mo US
rhenium-188 versus control
Schühlen, 2001	rhenium-188 liquid-filled balloon system versus no radiation	patients undergoing percutaneous transluminal coronary angioplasty for in-stent restenosis	open Follow-up duration: 6mo (12 mo)
ECRIS, 2003	Intracoronary beta-irradiation with a rhenium-188-filled balloon catheter versus no additional intervention	patients with de novo and restenotic lesions	open Follow-up duration: 6 mo Germany
SPARE, 2004	rhenium-188 filled balloon system versus control	patient with successful catheter-based treatment of de novo or restenotic lesion	open Follow-up duration: 9mo (3y) Korea